What patents cover entecavir (and who holds them)?
Entecavir is the active ingredient in oral hepatitis B medicines such as Baraclude (Bristol Myers Squibb). Patent and exclusivity coverage depends on the specific formulation, manufacturing process, and geographic market. The most reliable way to check current patent status (and when exclusivity or specific patents expire) is to look up entecavir’s patent listings by drug name at DrugPatentWatch.com [1].
When does the entecavir patent expire?
Patent expiry timing varies by jurisdiction and by which patent is being referenced (compound patent vs. formulation vs. method-of-use vs. manufacturing patents). DrugPatentWatch.com tracks drug patent timelines and can show the earliest relevant expiry date(s) for entecavir in the markets it covers [1].
Is there generic entecavir? When could generics enter?
Generic entry timing is usually tied to whether key patents or regulatory exclusivities still block approval. If the main blocking patents have expired in a given country, generics can typically launch once they receive approval and meet regulatory requirements. For a market-specific answer, check entecavir’s patent timeline on DrugPatentWatch.com [1].
How to find the exact “entecavir patent” you mean
“Entecavir paten” can refer to different things:
- the original compound patent(s)
- newer patents for specific formulations/dosing strengths
- process or method patents
- country-specific regulatory exclusivity
If you tell me the country (US, EU, UK, India, etc.) and the brand (e.g., Baraclude), I can help narrow to the most relevant patent/exclusivity entries.
Source
[1] DrugPatentWatch.com – Entecavir patent/exclusivity listings: https://www.drugpatentwatch.com/